Tracers / [177Lu]Lu-DOTA-iPD-L1
[177Lu]Lu-DOTA-iPD-L1
Also written as [Lu-177]Lu-DOTA-iPD-L1
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- PD-L1 inhibitor cyclic peptide conjugated with DOTA chelator
- Target / mechanism
- Targets programmed cell death ligand-1 (PD-L1), overexpressed in certain tumors, which inhibits immune response PMID 40733128
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC | — | 98.9 ± 1.1% | DOTA-iPD-L1 | 40733128 2025 Pharmaceutics [177Lu]Lu-DOTA-iPD-L1 was also prepared for comparative imaging studies, as previously reported [12] |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-iPD-L1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40733128. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.